search
Back to results

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Primary Purpose

Relapsing Multiple Sclerosis (RMS)

Status
Enrolling by invitation
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Ublituximab
Sponsored by
TG Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Relapsing Multiple Sclerosis (RMS)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Participants must meet the following criteria:

  1. Complete the 96-week double-blind TG1101-RMS301 (NCT03277261) or TG1101-RMS302 (NCT03277248) study or complete the final Week 208 visit of the TG1101-RMS201E (NCT03381170) study
  2. Investigator believes may benefit from treatment with ublituximab
  3. Are able and willing to provide written informed consent (e.g., before the first infusion) and to comply with the study protocol
  4. Female participants of child-bearing potential, and male partners must consent to use a medically acceptable method of contraception from consent, throughout the study period, and for 20 weeks after the last dose of ublituximab

Exclusion Criteria:

Participants who meet any of the following exclusion criteria are not to be enrolled to this study:

  1. Any significant or uncontrolled medical condition or treatment-emergent, clinically significant laboratory abnormality such as:

    1. Absolute neutrophil count < 1.5 x 10e3/µL
    2. Hematocrit < 24%
    3. Platelet count < 150,000 cell/mm^3
    4. Hypogammaglobulinemia immunoglobulin G (IgG) < 4.0g/L
  2. Active infection
  3. Ongoing pregnancy (female participants)
  4. Participants who discontinued ublituximab treatment or withdrew consent from the TG1101-RMS301 or TG1101-RMS302 study during the 96-week evaluation period or prior to completing the final Week 208 visit of the TG1101-RMS201E study
  5. Participants who have started any disease modifying therapy (DMT), stem cell transplantation, or participation in any other interventional clinical trial after completion of the 96-week visit in the TG1101-RMS301, TG1101-RMS302, or after completing the final Week 208 visit of the TG1101-RMS201E study
  6. Participants who have had a confirmed multiple sclerosis (MS) relapse within the past 30 days prior to Week 1 Day 1 (W1D1). Following a relapse, participants must be neurologically stable for at least 30 days prior to screening or W1D1 of the OLE
  7. Participants with unstable disease activity
  8. Presence of malignancy, except for surgically excised basal or squamous cell skin lesions
  9. Vaccination with live virus within 2 months of randomization

Sites / Locations

  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site
  • TG Therapeutics Investigational Trial Site

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Ublituximab Infusions

Arm Description

RMS301/RMS302: All participants transferring from RMS301/RMS302 who sign consent for this study will receive an initial 4-hour infusion of 150 mg ublituximab on Week 1 (Day 1) followed by a 1-hour infusion of 450 mg ublituximab 14 days later Week 3 (Day 15). Subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312. RMS201E: All participants transferring from RMS201E who sign consent for this study will receive a 1-hour infusion of 450 mg ublituximab on Week 1 (Day 1) and subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312. For all participants (RMS301/RMS302/RMS201E), infusion treatment will continue for 312 weeks, or until physician or participant decision to withdraw from the study

Outcomes

Primary Outcome Measures

Annualized Relapse Rate (ARR)
ARR is defined as the number of relapses per-participant year. The estimate of ARR will be the total number of relapses divided by the sum of duration on study treatment (years).

Secondary Outcome Measures

Full Information

First Posted
October 16, 2019
Last Updated
October 18, 2023
Sponsor
TG Therapeutics, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT04130997
Brief Title
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Official Title
An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Enrolling by invitation
Study Start Date
November 18, 2019 (Actual)
Primary Completion Date
April 2027 (Anticipated)
Study Completion Date
April 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
TG Therapeutics, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
Detailed Description
TG1101-RMS303 is an open-label, single-arm extension study designed to evaluate long-term safety and efficacy of ublituximab in participants with RMS. Participants who complete the 96-week, double-blind treatment period of TG1101-RMS301 (RMS301 [NCT03277261]) or TG1101-RMS302 (RMS302 [NCT03277248]) are eligible for participation in this Open Label Extension (OLE) study. Participants may also be eligible for TG1101-RMS303 if they have completed Week 208 of TG1101-RMS201E (RMS201E [NCT03381170]) (United States of America [USA] participants only).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Relapsing Multiple Sclerosis (RMS)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Model Description
open-label, single-arm, extension study
Masking
None (Open Label)
Allocation
N/A
Enrollment
1100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Ublituximab Infusions
Arm Type
Experimental
Arm Description
RMS301/RMS302: All participants transferring from RMS301/RMS302 who sign consent for this study will receive an initial 4-hour infusion of 150 mg ublituximab on Week 1 (Day 1) followed by a 1-hour infusion of 450 mg ublituximab 14 days later Week 3 (Day 15). Subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312. RMS201E: All participants transferring from RMS201E who sign consent for this study will receive a 1-hour infusion of 450 mg ublituximab on Week 1 (Day 1) and subsequent infusions of ublituximab will be administered at 450 mg for 1-hour every 24 weeks from Weeks 24 to 312. For all participants (RMS301/RMS302/RMS201E), infusion treatment will continue for 312 weeks, or until physician or participant decision to withdraw from the study
Intervention Type
Biological
Intervention Name(s)
Ublituximab
Other Intervention Name(s)
TG-1101
Intervention Description
Ublituximab (TG-1101) is a recombinant chimeric monoclonal antibody targeting CD20, available as a 25 mg/mL concentrate for intravenous use, supplied by TG Therapeutics, Inc.
Primary Outcome Measure Information:
Title
Annualized Relapse Rate (ARR)
Description
ARR is defined as the number of relapses per-participant year. The estimate of ARR will be the total number of relapses divided by the sum of duration on study treatment (years).
Time Frame
Up to Week 336

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Participants must meet the following criteria: Complete the 96-week double-blind TG1101-RMS301 (NCT03277261) or TG1101-RMS302 (NCT03277248) study or complete the final Week 208 visit of the TG1101-RMS201E (NCT03381170) study Investigator believes may benefit from treatment with ublituximab Are able and willing to provide written informed consent (e.g., before the first infusion) and to comply with the study protocol Female participants of child-bearing potential, and male partners must consent to use a medically acceptable method of contraception from consent, throughout the study period, and for 20 weeks after the last dose of ublituximab Exclusion Criteria: Participants who meet any of the following exclusion criteria are not to be enrolled to this study: Any significant or uncontrolled medical condition or treatment-emergent, clinically significant laboratory abnormality such as: Absolute neutrophil count < 1.5 x 10e3/µL Hematocrit < 24% Platelet count < 150,000 cell/mm^3 Hypogammaglobulinemia immunoglobulin G (IgG) < 4.0g/L Active infection Ongoing pregnancy (female participants) Participants who discontinued ublituximab treatment or withdrew consent from the TG1101-RMS301 or TG1101-RMS302 study during the 96-week evaluation period or prior to completing the final Week 208 visit of the TG1101-RMS201E study Participants who have started any disease modifying therapy (DMT), stem cell transplantation, or participation in any other interventional clinical trial after completion of the 96-week visit in the TG1101-RMS301, TG1101-RMS302, or after completing the final Week 208 visit of the TG1101-RMS201E study Participants who have had a confirmed multiple sclerosis (MS) relapse within the past 30 days prior to Week 1 Day 1 (W1D1). Following a relapse, participants must be neurologically stable for at least 30 days prior to screening or W1D1 of the OLE Participants with unstable disease activity Presence of malignancy, except for surgically excised basal or squamous cell skin lesions Vaccination with live virus within 2 months of randomization
Facility Information:
Facility Name
TG Therapeutics Investigational Trial Site
City
Pasadena
State/Province
California
ZIP/Postal Code
91105
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Denver
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Northbrook
State/Province
Illinois
ZIP/Postal Code
60062
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Las Vegas
State/Province
Nevada
ZIP/Postal Code
89106
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Teaneck
State/Province
New Jersey
ZIP/Postal Code
07666
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Albuquerque
State/Province
New Mexico
ZIP/Postal Code
87131
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Amherst
State/Province
New York
ZIP/Postal Code
14266
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43214
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Westerville
State/Province
Ohio
ZIP/Postal Code
43081
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Knoxville
State/Province
Tennessee
ZIP/Postal Code
37922
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Frisco
State/Province
Texas
ZIP/Postal Code
75034
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Round Rock
State/Province
Texas
ZIP/Postal Code
78681
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78258
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Facility Name
TG Therapeutics Investigational Trial Site
City
Grodno
ZIP/Postal Code
230017
Country
Belarus
Facility Name
TG Therapeutics Investigational Trial Site
City
Grodno
ZIP/Postal Code
320017
Country
Belarus
Facility Name
TG Therapeutics Investigational Trial Site
City
Minsk
ZIP/Postal Code
220114
Country
Belarus
Facility Name
TG Therapeutics Investigational Trial Site
City
Minsk
ZIP/Postal Code
220116
Country
Belarus
Facility Name
TG Therapeutics Investigational Trial Site
City
Minsk
ZIP/Postal Code
220226
Country
Belarus
Facility Name
TG Therapeutics Investigational Trial Site
City
Osijek
ZIP/Postal Code
31000
Country
Croatia
Facility Name
TG Therapeutics Investigational Trial Site
City
Varazdin
ZIP/Postal Code
42000
Country
Croatia
Facility Name
TG Investigational Trial Site
City
Zagreb
ZIP/Postal Code
10000
Country
Croatia
Facility Name
TG Therapeutics Investigational Trial Site
City
Tbilisi
ZIP/Postal Code
00112
Country
Georgia
Facility Name
TG Therapeutics Investigational Trial Site
City
Tbilisi
ZIP/Postal Code
00114
Country
Georgia
Facility Name
TG Therapeutics Investigational Trial Site
City
Tbilisi
ZIP/Postal Code
00159
Country
Georgia
Facility Name
TG Therapeutics Investigational Trial Site
City
Tbilisi
ZIP/Postal Code
00160
Country
Georgia
Facility Name
TG Therapeutics Investigational Trial Site
City
Tbilisi
ZIP/Postal Code
00172
Country
Georgia
Facility Name
TG Therapeutics Investigational Trial Site
City
Tbilisi
ZIP/Postal Code
00179
Country
Georgia
Facility Name
TG Therapeutics Investigational Trial Site
City
Katowice
ZIP/Postal Code
40-555
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Katowice
ZIP/Postal Code
40-568
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Katowice
ZIP/Postal Code
40-684
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Kraków
ZIP/Postal Code
31-505
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Olsztyn
ZIP/Postal Code
10-561
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Poznań
ZIP/Postal Code
61-583
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Warszawa
ZIP/Postal Code
04-141
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Zabrze
ZIP/Postal Code
04-749
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Łódź
ZIP/Postal Code
41-800
Country
Poland
Facility Name
TG Therapeutics Investigational Trial Site
City
Arkhangel'sk
ZIP/Postal Code
163045
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Barnaul
ZIP/Postal Code
656045
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Bryansk
ZIP/Postal Code
241033
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Chelyabinsk
ZIP/Postal Code
454021
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Ekaterinburg
ZIP/Postal Code
620102
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Kemerovo
ZIP/Postal Code
650066
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Krasnoyarsk
ZIP/Postal Code
660037
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Kursk
ZIP/Postal Code
305007
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Moscow
ZIP/Postal Code
125367
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Moscow
ZIP/Postal Code
127015
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Nizhny Novgorod
ZIP/Postal Code
603155
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Novosibirsk
ZIP/Postal Code
630007
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Novosibirsk
ZIP/Postal Code
630087
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Pyatigorsk
ZIP/Postal Code
357538
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Saint Petersburg
ZIP/Postal Code
197002
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Saint Petersburg
ZIP/Postal Code
197110
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Saint Petersburg
ZIP/Postal Code
197376
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Saransk
ZIP/Postal Code
430032
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Smolensk
ZIP/Postal Code
214018
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Tomsk
ZIP/Postal Code
634050
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Tyumen
ZIP/Postal Code
625000
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Ufa
ZIP/Postal Code
450005
Country
Russian Federation
Facility Name
TG Therapeutics Investigational Trial Site
City
Belgrade
ZIP/Postal Code
11000
Country
Serbia
Facility Name
TG Therapeutics Investigational Trial Site
City
Kragujevac
ZIP/Postal Code
34000
Country
Serbia
Facility Name
TG Therapeutics Investigational Trial Site
City
Cherkasy
ZIP/Postal Code
18009
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Chernihiv
ZIP/Postal Code
14001
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Chernihiv
ZIP/Postal Code
14029
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Chernivtsi
ZIP/Postal Code
58002
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Ivano-Frankivs'k
ZIP/Postal Code
76008
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Kharkiv
ZIP/Postal Code
61058
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Kharkiv
ZIP/Postal Code
61103
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Kharkiv
ZIP/Postal Code
61176
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Kyiv
ZIP/Postal Code
03037
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Kyiv
ZIP/Postal Code
03115
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Lviv
ZIP/Postal Code
79000
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Lviv
ZIP/Postal Code
79010
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Odesa
ZIP/Postal Code
65009
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Poltava
ZIP/Postal Code
36011
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Ternopil
ZIP/Postal Code
46027
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Vinnytsya
ZIP/Postal Code
21005
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Zaporizhia
ZIP/Postal Code
69065
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Zaporizhia
ZIP/Postal Code
96900
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Zhytomyr
ZIP/Postal Code
10002
Country
Ukraine
Facility Name
TG Therapeutics Investigational Trial Site
City
Úzhgorod
ZIP/Postal Code
88018
Country
Ukraine

12. IPD Sharing Statement

Learn more about this trial

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

We'll reach out to this number within 24 hrs